TABLE 1.
Demographic and Clinical Characteristics of 183 Subjects With Body Dysmorphic Disorder (BDD) at Intake Assessment
| Variable | N | % | Mean | SD |
|---|---|---|---|---|
| Female | 124 | 67.8 | ||
| Race/ethnicitya | ||||
| White | 155 | 85.6 | ||
| Hispanic | 12 | 8.7 | ||
| Marital status | ||||
| Single (never married) | 116 | 63.4 | ||
| Married | 46 | 25.1 | ||
| Divorced or separated | 20 | 10.9 | ||
| Widowed | 1 | 0.5 | ||
| Education | ||||
| High school, General Educational Development (GED) Test, or less | 52 | 28.4 | ||
| Completed some college | 55 | 30.1 | ||
| Graduated from a 2-year college | 10 | 5.5 | ||
| Graduated from a 4-year college | 39 | 21.3 | ||
| Completed some graduate school | 10 | 5.5 | ||
| Graduated from graduate school | 17 | 9.3 | ||
| Employed full-time | 71 | 38.8 | ||
| Met full DSM-IV BDD criteria at intakeb | 161 | 88.5 | ||
| BDD is most problematic lifetime disorder (N=110)c | 85 | 77.3 | ||
| BDD is most problematic current disorder (N=155)c | 118 | 76.1 | ||
| Continuous course of BDD (past course)d | 148 | 81.3 | ||
| Mental health treatment at intake | 124 | 67.8 | ||
| Outpatient | 116 | 63.4 | ||
| Inpatient, partial hospitalization, or residential | 8 | 4.4 | ||
| Mental health treatment at intake | ||||
| Medication onlye | 52 | 28.4 | ||
| Therapy only | 31 | 16.9 | ||
| Both medication and therapye | 41 | 22.4 | ||
| Age | 33.1 | 12.2 | ||
| BDD severity (score on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder)f | 30.0 | 6.9 | ||
| Global Assessment of Functioning Scale score | 45.6 | 11.0 | ||
| Age at onset of BDD | 16.5 | 7.1 | ||
| Duration of BDD (years) | 16.0 | 12.5 |
Nonwhite races: black (N=14, 7.7%), American Indian (N=11, 6.0%), Asian (N=2, 1.1%), and Native Hawaiian/Pacific Islander (N=1, 0.5%).Some subjects endorsed more than one nonwhite race.
Fourteen members of the group (7.7%) were in partial remission from BDD at intake, and seven (3.8%) were in full remission, based on the psychiatric status rating scale. All subjects met full DSM-IV criteria for BDD currently or in the past.
In the subject’s opinion.
Retrospectively assessed lifetime course; “continuous” means that symptoms had not remitted for at least 1 month since the initial onset.
Types of medications: serotonin reuptake inhibitors (N=76, 41.5%), non-SRIs (N=36, 19.7%), benzodiazepines (N=26, 14.2%), mood stabilizers (N=17, 9.3%), antipsychotics (N=16, 8.7%), buspirone (N=12, 6.6%), stimulants (N=5, 2.7%), nonbenzodiazepine anxiolytics (N=4, 2.2%), and nonbenzodiazepine sedatives (N=3, 1.6%).
The score on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder is reported for only the 161 subjects who met full criteria for BDD at the intake evaluation. The mean score for the entire group was 27.2 (SD=10.2).